Abstract
AbstractAntibody discovery is bottlenecked by the individual expression and evaluation of antigen-specific hits. Here, we address this gap by developing an automated workflow combining cell-free DNA template generation, protein synthesis, and high-throughput binding measurements of antibody fragments in a process that takes hours rather than weeks. We apply this workflow to 119 published SARS-CoV-2 neutralizing antibodies and demonstrate rapid identification of the most potent antibody candidates.
Publisher
Cold Spring Harbor Laboratory
Reference53 articles.
1. Lateral flow assays
2. Development of therapeutic antibodies for the treatment of diseases
3. 2020 FDA drug approvals
4. FDA. Emergency Use Authorization for REGEN-COV (Casirivimab and Imdevimab). https://www.fda.gov/media/145610/download (2020).
5. FDA. Emergency Use Authorization for Bamlanivimab and Etesevimab. https://www.fda.gov/media/145801/download (2020).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献